655 related articles for article (PubMed ID: 18076219)
1. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
Darwish M; Kirby M; Robertson P; Hellriegel ET
Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
[TBL] [Abstract][Full Text] [Related]
2. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis.
Jenkins J; Williams D; Deng Y; Collins DA; Kitchen VS
Eur J Clin Pharmacol; 2010 Jan; 66(1):67-76. PubMed ID: 19756558
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
Turpault S; Brian W; Van Horn R; Santoni A; Poitiers F; Donazzolo Y; Boulenc X
Br J Clin Pharmacol; 2009 Dec; 68(6):928-35. PubMed ID: 20002088
[TBL] [Abstract][Full Text] [Related]
4. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
5. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
7. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
[TBL] [Abstract][Full Text] [Related]
8. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole.
Wang LS; Zhou G; Zhu B; Wu J; Wang JG; Abd El-Aty AM; Li T; Liu J; Yang TL; Wang D; Zhong XY; Zhou HH
Clin Pharmacol Ther; 2004 Mar; 75(3):191-7. PubMed ID: 15001970
[TBL] [Abstract][Full Text] [Related]
9. Systemic exposure to armodafinil and its tolerability in healthy elderly versus young men: an open-label, multiple-dose, parallel-group study.
Darwish M; Kirby M; Hellriegel ET; Yang R; Robertson P
Drugs Aging; 2011 Feb; 28(2):139-50. PubMed ID: 21275439
[TBL] [Abstract][Full Text] [Related]
10. Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
Armani S; Ting L; Sauter N; Darstein C; Tripathi AP; Wang L; Zhu B; Gu H; Chun DY; Einolf HJ; Kulkarni S
Clin Drug Investig; 2017 May; 37(5):465-472. PubMed ID: 28155129
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies.
Darwish M; Kirby M; Hellriegel ET; Yang R; Robertson P
Clin Drug Investig; 2009; 29(2):87-100. PubMed ID: 19133704
[TBL] [Abstract][Full Text] [Related]
12. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals.
Wang X; Dowty ME; Tripathy S; Le VH; Huh Y; Curto M; Winton JA; O'Gorman MT; Chan G; Malhotra BK
Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):367-381. PubMed ID: 38554232
[TBL] [Abstract][Full Text] [Related]
14. Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach.
Lammers LA; Achterbergh R; van Schaik RHN; Romijn JA; Mathôt RAA
Clin Pharmacokinet; 2017 Oct; 56(10):1231-1244. PubMed ID: 28229374
[TBL] [Abstract][Full Text] [Related]
15. Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
Någård M; Ah-See ML; Strauss J; Wise-Draper T; Safran HP; Nadeau L; Edenfield WJ; Lewis LD; Ottesen LH; Li Y; Mugundu GM
Cancer Chemother Pharmacol; 2023 Sep; 92(3):193-203. PubMed ID: 37394627
[TBL] [Abstract][Full Text] [Related]
16. Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach.
Kim MG; Kim Y; Jeon JY; Kim DS
Br J Clin Pharmacol; 2016 Dec; 82(6):1580-1590. PubMed ID: 27495955
[TBL] [Abstract][Full Text] [Related]
17. Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long-lasting Inhibition of CYP2C19.
Kaartinen TJK; Tornio A; Tapaninen T; Launiainen T; Isoherranen N; Niemi M; Backman JT
Clin Pharmacol Ther; 2020 Dec; 108(6):1254-1264. PubMed ID: 32558923
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Drug-Drug Interaction Potential of Enarodustat (JTZ-951) Using a Cytochrome P450 Probe Cocktail.
Pai SM; Yamada H; Murata H
Clin Pharmacol Drug Dev; 2023 Jul; 12(7):667-682. PubMed ID: 37269147
[TBL] [Abstract][Full Text] [Related]
19. Assessment of cytochrome P450 activity by a five-drug cocktail approach.
Zhu B; Ou-Yang DS; Chen XP; Huang SL; Tan ZR; He N; Zhou HH
Clin Pharmacol Ther; 2001 Nov; 70(5):455-61. PubMed ID: 11719732
[TBL] [Abstract][Full Text] [Related]
20. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]